Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.21.

EBIT: As of FY2025 Q3, the actual value is USD -292.67 K.

General and Administrative Expenses

• For the three months ended September 30, 2025, expenses were $235,955, compared to $749,158 for the same period in 2024. For the nine months ended September 30, 2025, expenses were $763,088, compared to $1,882,579 in 2024.

Net Loss

• For the three months ended September 30, 2025, the net loss was approximately $1,300,000, compared to a net income of $326,000 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was approximately $1,700,000, compared to a net loss of $1.4 million in 2024.

Net Cash Used in Operating Activities

• For the nine months ended September 30, 2025, net cash used in operating activities was - $410,927, compared to - $626,508 for the same period in 2024.

Income from Investments Held in Trust Account

• For the three months ended September 30, 2025, income was $56,719, compared to $147,634 for the same period in 2024. For the nine months ended September 30, 2025, income was $168,010, compared to $636,883 in 2024.

Future Outlook and Strategy

• Core Business Focus: The company has until November 15, 2026, to consummate an initial Business Combination. If not completed by this date, the company must cease operations, redeem public shares, and liquidate.
• Non-Core Business: The company is exploring a Business Combination with Phytanix Bio, which involves merging with CB Merger Sub and Phytanix Merger Sub, with the company and Phytanix becoming wholly owned subsidiaries of HoldCo.